José Lopes, PhD,  managing science editor—

In contrast to what is often assumed, new research suggests that clumps of the protein TDP-43 — a hallmark of amyotrophic lateral sclerosis (ALS) — actually protect nerve cells rather than harm them. If this finding confirmed in future studies, it could hugely impact how ALS and other neurodegenerative diseases…

After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with companies early on in the product development process, access to…

Daiichi Sankyo is looking to market the amyotrophic lateral sclerosis (ALS) treatment Radicava (edaravone) in Brazil after reaching a licensing agreement with the therapy’s maker, Mitsubishi Tanabe Pharma. The company will submit a regulatory application through its local subsidiary, and expects to commercialize Radicava in the…

The benefits of riluzole, an approved treatment for amyotrophic lateral sclerosis (ALS), is thought to partly lie in its antioxidant effects. A new study now reports that this activity can be enhanced by combining it with agents like Radicava that provide protection via different pathways. The study, “…

Daily use of levosimendan capsules appear to preserve respiratory strength in people with amyotrophic lateral sclerosis (ALS) while in a supine, or lying flat, position, a sub-analysis of the Phase 2 LEVALS trial reports. Treatment did not show significant benefit against placebo when patients were sitting up, its primary…

Assessing the degree of atrophy, or shinkage, in facial nerves with a high-resolution imaging tool appears to provide an accurate and early diagnosis of amyotrophic lateral sclerosis (ALS), according to new research. The study, “Facial nerve atrophy in patients with amyotrophic lateral sclerosis: Evaluation with fast…

People with amyotrophic lateral sclerosis (ALS) have higher blood serum levels of neurofilament light chain (sNfL) than do healthy people, a new study found. Its work also further supported sNfL’s usefulness as a marker of likely disease progression and outcomes, with higher concentrations indicating poorer survival. The research, “…

Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study into arimoclomol, a potential oral treatment for amyotrophic lateral sclerosis (ALS). ORARIALS-01 is a randomized, placebo-controlled and double-blind trial (NCT03491462) underway at 30 centers across North America…

Amyotrophic lateral sclerosis (ALS) progression is associated with higher levels of specific lipids in the spinal cord and changes in their metabolism, a study in a rat model of the disease reports. These findings may represent a defense mechanism against oxidative damage, as well as a potential treatment route for…

A $3.1 million grant from the National Institute on Aging (NIA) is intended to help two scientists at Northwestern University find new treatments for amyotrophic lateral sclerosis (ALS). The grant was awarded to P. Hande Ozdinler, PhD, a professor of neurology at the university’s Feinberg…